Business
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference ...
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to
About this update from Acrivon Therapeutics, Inc.
[{"type":"text","content":"Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics \n WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced that two abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held from October 11-15, 2023 in Boston. “Acrivon Predictive Precision Proteomics (AP3) is a pioneering, next-generation precision medicine approach engineered to overcome the limitations of traditional genetics-based approaches, and we are excited to provide insights into our drug-tailored ACR-368 OncoSignature patient responder identification test that we are currently using in our ongoing clinical trial for patient selection,\" said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. Abstracts Accepted for Poster Presentation Title:Validation of the OncoSignature assay, an ACR-368-tailored response-predictive quantitative multiplexed immunofluorescent assay for prediction of sensitivity to the CHK1/2 inhibitor ACR-368 in individual patients with cancerPoster Number:B012Presenter:Michail Shipitsin, vice president of biomarker development, Acrivon TherapeuticsDate and Time:Friday, October 13 | 12:30-4:00 p.m. ETTitle:Identification of biomarkers predictive of sensitivity to the CHK1/2 inhibitor ACR-368 using high-resolution phosphoproteomics and development of an ACR-368-tailored patient responder identification 3-marker test, ACR-368 OncoSignaturePoster Number:C002Presenter:Caroline Wigerup, director of biology, Acrivon TherapeuticsDate and Time:Saturday, October 14 | 12:30-4:00 p.m. ET About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that ...